BP-PC-001

BP-PC-001, a Phase I/II clinical trial of BPX-101 (formerly BP-GMAX-CD1) plus AP1903 in men with metastatic castrate resistant prostate cancer, sponsored by Bellicum Pharmaceuticals, is fully enrolled at the University of Texas Health Science Center – Houston.

For reference, you may view the protocol synopsis at www.clinicaltrials.gov